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ABSTRACT 
 Worldwide, more than half of all HIV-infected individuals are women. Since mucosal 
surfaces are the primary gateway for HIV entry, maintaining the integrity of the female 
reproductive tract (FRT) is essential for preventing infection. The FRT employs many immune 
mechanisms that serve as the first line of defense against HIV transmission. Among these are 
vaginal fluid secretions rich in antimicrobial peptides, and commensal bacteria that colonize the 
vagina and prevent infections. We sought to study vaginal fluid as an innate immune component 
of the FRT in the prevention of HIV infection. Additionally, we investigated the anti-HIV 
microbicide candidate RC-101 as a possible treatment against pathogenic bacteria that disrupt the 
healthy microbiota of the FRT and create a suboptimal immune state that increases host 
susceptibility to viruses, such as HIV. 
 Here we report that vaginal fluid collected from healthy females inhibits HIV infection. 
Moreover, our studies reveal that vaginal fluid collected from Black and White women exhibit 
disparate anti-HIV activity, possibly rendering Black women more susceptible to HIV infection. 
In addition, we show that RC-101, which is active against HIV, can also inhibit pathogenic 
bacteria that compromise FRT innate immunity, providing a dual mechanism of protection 
against HIV acquisition. 
 Overall, these findings show that vaginal fluid is an important part of female innate 
immunity that protects the host from heterosexual HIV acquisition. Furthermore, the microbicide 
RC-101 may prevent HIV infection by both directly preventing viral entry, and by restricting the 
growth of pathogenic bacteria that disrupt the protective commensal vaginal flora. Together, 
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innate mechanisms and bolstered protection present a multifaceted approach to maintaining 
effective host immunity. 
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CHAPTER ONE: INTRODUCTION 
 Globally, there are 33 million people living with human immunodeficiency virus (HIV) 
(1). Although HIV constitutes a worldwide epidemic, Africa bears most of the burden in the total 
number of infections. In fact, sub-Saharan Africa has the highest prevalence accounting for as 
much as 68% of all HIV positive individuals (1). Importantly, nearly 60% of those infected in 
sub-Saharan Africa are women, a trend that carries over to the global landscape, where women 
also constitute more than half of all HIV infections (1,2). This observed gender discrepancy 
warrants a closer look at the possible molecular mechanisms behind increased susceptibility of 
women to HIV acquisition. 
 The primary sites of HIV infection are mucosal tissues, such as vaginal and rectal 
mucosa, where the virus can breach the surface epithelium and gain access to more susceptible 
cells in the underlying tissue (2-4). Given that heterosexual HIV transmission constitutes the 
main mode of infection for women, the female reproductive tract (FRT) represents the primary 
gateway of entry for HIV (1,2,5,6). Here, vaginal and cervical epithelia are bathed in mucosal 
fluid secretions from endometrial and oviductal fluids, cervical vestibular glands, and plasma 
transudate (7). This fluid provides multiple modes of innate defense in the FRT. The vagina 
regularly sloughs off the fluid and epithelial cells, which serves to remove invading microbes (8). 
Moreover, the contents of these secretions are pivotal contributors to the innate immunity of the 
FRT. Vaginal fluid is comprised of a complex mixture of antimicrobial peptides and other 
proteins that together actively fight pathogens threatening to disrupt the integrity of the vaginal 
environment (5,9,10).  
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 Generally, most antimicrobial peptides and proteins present in vaginal fluid act as 
microbicides targeted towards bacteria, fungi, and viruses. These antimicrobial agents include 
lactoferrin, calprotectin, lysozyme, secretory leukocyte inhibitor (SLPI), human neutrophil 
peptides (HNP1-3), and human beta defensins (HBDs) (9,10). Only recently have studies shown 
that several of these peptides confer anti-HIV protection in the human host (8). For instance, 
HBDs have been shown to regulate the CXCR4 co-receptor in T-cells, thereby halting viral 
entry. HNPs have also been shown to inhibit HIV replication via two mechanisms: in the absence 
of serum, HNPs inhibit replication before viral integration in T-cells; in the presence of serum, 
they prevent nuclear translocation of the viral genome and block genomic transcription of the 
virus (11-13). Although each cationic antimicrobial peptide functions by distinct mechanisms to 
inhibit HIV entry and replication, no single peptide is responsible for conferring full antiviral 
immunity to the host. Rather, the antiviral activity of these antimicrobial peptides is dependent 
on their synergistic activity in vaginal fluid, where they work in concert to prevent HIV infection 
(8,9). Antimicrobial peptides, therefore, act as effector molecules of FRT innate immunity that 
serve to protect the mucosal integrity of the genital tract (5). Yet, what remains elusive is 
whether these vaginal antimicrobial peptides are capable of exerting antiviral properties against 
all HIV strains. Interestingly, there is a link between distinct HIV subtypes and geographical 
regions, with different clades being more prevalent in particular locations around the world (14). 
Elucidating the ability of vaginal fluid to protect the host from diverse HIV isolates is critical in 
establishing the versatility of FRT innate immunity. Furthermore, the possibility that 
immunological differences among hosts determine HIV susceptibility and subsequent subtype 
distribution has yet to be studied. In support of this hypothesis, additional studies have 
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characterized differences in the expression of antimicrobial peptides among ethnic groups that 
may lead to differential HIV susceptibility (15). Elucidating FRT innate immune differences 
among distinct racial groups is essential in identifying ethnic backgrounds that are intrinsically 
more susceptible to HIV infection. 
 In addition to the presence of antimicrobial peptides, the vagina is host to a myriad of 
microbes that play a role in maintaining the FRT free of pathogenic organisms (16,17). The 
normal vaginal flora is comprised of lactobacillus species that secrete lactic acid and hydrogen 
peroxide, maintaining an acidic milieu inhospitable to many pathogens (17,18). Certain vaginal 
infections can disrupt the healthy vaginal microbiota and give rise to numerous disease states. 
Bacterial vaginosis (BV) is the most prevalent vaginal infection that compromises the innate host 
defenses and renders the FRT susceptible to foreign invaders (16,17). BV is a transient condition 
that affects up to 30% of females in the United States and is also the primary reason women seek 
gynecological care. BV is characterized by colonization of mixed anaerobic bacteria, such as 
Atopobium vaginae, Mobiluncus curtisii, Gardnerella vaginalis, and Prevotella bivia, that come 
into contact with epithelial cells of the FRT and disrupt commensal microflora (5,16,17). BV is 
associated with a higher susceptibility to acquisition of sexually transmitted diseases, such as 
HIV, and an increased rate of medical complications including pre-term birth and pelvic 
inflammatory disease (17,19). Yet, the interaction of BV bacteria with the FRT innate immune 
system is not well understood, and therefore the mechanism by which BV induces its 
pathological effects remains elusive. Previous studies performed by Valore and colleagues have 
shown that women experiencing BV have vaginal fluid deficient in key antimicrobial peptides 
(9). Compared to healthy women, vaginal lavage fluid of women with BV had decreased 
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concentrations of HNPs, SLPI, and HBDs, which are essential cationic peptides that help 
maintain innate immune competence in the FRT (9,10). As a result, finding effective treatments 
to combat BV is an essential component in the attempt to maintain an intact FRT equipped to 
mount an immune response to potentially harmful microbes.  
 A promising candidate, RC-101, has emerged as a possible treatment for BV. RC-101 is a 
circular cationic retrocyclin analog composed of 18 residues and three cysteine disulfide bonds 
(20). Retrocyclins are host defense peptides encoded in the human genome, expressed as 
transcripts, but not transcribed due to a premature stop codon. Solid phase synthesis has allowed 
us to recreate and study these lost defense peptides, which exhibit antimicrobial activity (20-23). 
RC-101 synthesis results in a peptide highly similar to the intact retrocyclin gene with the 
exception of a single amino acid substitution, which replaces an arginine residue with lysine 
(21). Currently, RC-101 is being developed as a topical microbicide for the prevention of 
heterosexual HIV acquisition. This antimicrobial peptide inhibits HIV entry by blocking the 6 
helix bundle formation of gp41, an envelope glycoprotein that assists fusion of the virus to host 
cells (20,22). Importantly, previous studies have demonstrated that RC-101 is non-cytotoxic, 
non-immunostimulatory, and above all remains stable in the harsh conditions of the vagina 
(20,23). Although recent studies have focused on the antiviral activity of RC-101, our findings 
suggest that RC-101 may also act as a bactericidal agent against pathogenic bacteria common in 
BV, while leaving the commensal vaginal microflora intact. A microbicide that helps maintain a 
healthy vaginal microbiota, while simultaneously preventing HIV infection represents an optimal 
prophylactic treatment against pathogens that threaten the genital mucosa. 
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 In the current study, we sought to elucidate the mechanisms by which the FRT maintains 
immune competence against potential pathogens. We reveal that vaginal fluid confers antiviral 
properties against diverse clinical HIV strains. Notably, vaginal fluid from Black females is less 
effective at inhibiting HIV infection compared to vaginal fluid from White females. 
Additionally, we show that RC-101 inhibits the growth of BV-associated bacteria that disrupt the 
healthy microbiota of the FRT. Collectively, these studies suggest that vaginal fluid, an essential 
innate immune component, confers disparate protection to Black and White women against 
diverse strains of HIV. Furthermore, the microbicide candidate RC-101 can inhibit BV-
associated bacteria, effectively supplementing FRT innate immunity and bolstering host defenses 
against potential pathogens.  
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CHAPTER TWO: MATERIALS AND METHODS 
Collection and Processing of Vaginal Fluid 
 Vaginal fluid was collected from postmenarcheal, but premenopausal, female donors 
according to the guidelines of the Institutional Review Board of the University of Central Florida 
(8). Female donors afflicted with recent or current vaginal infections or under antibiotic 
treatment were excluded from the study. Participating donors were asked to identify their race 
and ethnicity as part of an optional accompanying survey. Whole vaginal fluid samples were 
homogenized by sonication using a microtip ultrasound probe. Pools of vaginal fluid were 
created by combining equal volumes of vaginal fluid from between 5-12 donors, vortexing to 
mix thoroughly, and aliquoting for subsequent use. Vaginal fluid used for antiviral assays was 
acid-extracted and neutralized. 100 l of whole vaginal fluid was acid-extracted in 500 l of 
10% acetic acid. The sample was vigorously vortexed for 20 minutes at room temperature, then 
clarified by spinning at 13,000 rpm for 10 minutes at 4°C. The clarified supernatant was then 
transferred to a new tube and dried. The acid-extracted vaginal fluid was neutralized twice with 
water, each time diluting the acid ten-fold, before drying it down to a final volume of 50 l. The 
sample was then resuspended in 100 mM sodium phosphate, pH 7.4.  
Cell Lines and Viruses 
 TZM-bl cells, HeLa cell derivatives, were obtained from the National Institutes of Health 
AIDS Research and Reference Reagent Program. TZM-bl cells stably express CD4, CXCR4, and 
CCR5 receptors needed for HIV infection. This cell line also possesses a luciferase reporter gene 
under the control of HIV long terminal repeat region, which allows for accurate quantification of 
HIV infection. TZM-bl cells were grown in Dulbecco’s modified Eagle’s medium supplemented 
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with 100 units/ml penicillin, 100 μg/ml streptomycin, and 10% fetal bovine serum. The HIV 
strains BaL, 92UG037, 92US712, 93MW960, 92RW008, 91US005, 92UG037, and 94UG114, 
all R5 strains, were obtained from the National Institutes of Health AIDS Research and 
Reference Reagent Program. The 33015 clinical strain was a generous gift of Dr. Phalguni 
Gupta, University of Pittsburg, multicenter AIDS cohort study. 
Antiviral and Cytotoxicity Assays 
 TZM-bl cells were seeded at 5,000 cells/well in black 96-well microtiter plate with 
optically clear well bottoms. After 24 hrs, cells were treated with 50 l of culture medium 
containing acid-extracted vaginal fluid (neutralized with sodium hydroxide) at different dilutions 
(5%, 2.5%, and 1.25% final dilution) or a vehicle control (1X PBS). Immediately after treating 
the cells with vaginal fluid or vehicle 25 l of DEAE dextran was added to the cells (final 
concentration of 20 g/ml) along with 25 l of virus, diluted appropriately. After a 4 hr 
incubation, treatments were removed and replaced with 50 l of culture media and 50 l of acid-
extracted vaginal fluid at the appropriate dilutions. The cells were incubated for an additional 20 
hrs at 37°C/5% CO2. The cells were lysed and the amount of luciferase was quantified with 
Promega Bright-Glo reagent using an LMax luminometer. In parallel viability experminets, cell 
viability was determined by trypan blue exclusion assay, where the number of live cells treated 
with vaginal fluid and DEAE dextran was compared to PBS-treated cells with DEAE dextran. 
Bacterial Cultures  
 Mobiluncus curtisii, Atopobium vaginae, Prevotella bivia, and Gardnerella vaginalis 
were obtained from ATCC. All bacteria were cultured in tryptic soy broth with 5% rabbit’s 
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blood. Snap cultures of Mobiluncus curtisii, Atopobium vaginae, and Prevotella bivia were 
prepared and subsequently used for experiments. Gardnerella vaginalis was incubated 
aerobically in 37°C/5% CO2 until use in experiments.  
Bacterial Inhibition Assay 
 From snap cultures, bacteria were spun at 13,000 g for 5 minutes and resuspended in 
brain heart infusion media. Replicate cultures were mixed with different concentrations of RC-
101, also diluted in brain heart infusion media. Cultures were transferred to a Terasaki tray under 
3 μl liquid wax to prevent evaporation and incubated in anaerobic chambers at 37°C for 0, 8, 16, 
or 24 hrs. At each time point, the cultures were diluted in trypticase soy broth as necessary and 
plated on trypticase soy agar with 5% rabbit’s blood. The plates were incubated in anaerobic 
chambers for up to 1 week. The resulting colonies were manually counted to calculate culture 
density at each time and condition. 
Detection of RC-101 by Tris-Tricine Gel Electrophoresis 
 RC-101 (5 g/ml) was incubated at 37°C/5% CO2 with Mobiluncus curtisii, Atopobium 
vaginae, Prevotella bivia, and Gardnerella vaginalis for 24 hrs. Samples were acid-extracted 
with 5 volumes of 10% acetic acid and vigorously vortexed for 20 minutes. The samples were 
then spun at 13,000 rpm and the supernatant was transfered to new tubes. Samples were 
neutralized with water and dried down to near completion. All samples were then resuspended in 
sample buffer with 0.5 M dithiothreitol. A portion of each extract was run in a Tris-Tricine gel. 
Samples were then transferred to a polyvinylidene fluoride membrane and anti-RC-101 rabbit 
anitsera at 1:1000 was used to detect the presence of RC-101.  
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CHAPTER THREE: RESULTS 
Vaginal Fluid Inhibits Infection by Diverse Clinical Strains of HIV 
 Previous studies have shown that vaginal fluid inhibits HIV infection of lab adapted HIV 
strains (17). However, studies investigating the antiviral properties of vaginal fluid against 
diverse clinical strains of HIV have not been reported. Here we examined the ability of vaginal 
fluid to inhibit 7 different clinical strains of HIV (see Table 1). 
Strain Subtype Location 
93MW960 C Malawi 
92RW008 A Rwanda 
92UG037 A Uganda 
94UG114 D Uganda 
92US712 B United States 
91US005 B United States 
33015 B United States 
 
Table 1. HIV-1 Primary Clinical Isolates Tested to Demonstrate Clade Diversity. 
 TZM-bl cells were treated with acid-extracted vaginal fluid at 3 different final 
concentrations along with DEAE dextran and diluted viral inoculum. After 4 hrs of incubation, 
treatments were removed and vaginal fluid only was reapplied to the appropriate wells. After 24 
hrs infection levels were quantified by the amount of luciferase expressed in each condition. 
Figure 1 shows viral inhibition by vaginal fluid pooled from equal populations of Black and 
White donors. These mixed pools demonstrated inhibition of all HIV clinical strains at >80% by 
5% vaginal fluid. Furthermore, the mixed pools maintained at least 50% inhibition of all HIV 
strains at a vaginal fluid concentration of 2.5%. 
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Figure 1. Vaginal Fluid Pools Inhibit HIV Infection by Diverse Clinical Strains of HIV. 
Mixed vaginal fluid pools from both Black and White donors were assayed for their ability to inhibit HIV infection. Infection was 
quantified by measuring luciferase expression in each condition. Values were normalized to a media-only control and expressed as 
percent inhibition (n=3). The clade of each clinical isolate is given in parentheses. Error bars represent the SEM.  
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Vaginal Fluid from Black and White Females Confer Differential HIV Susceptibility 
 Additionally, we explored differences in infection by these clinical strains arising from 
intrinsic variability of vaginal fluid collected from Black and White females. We pooled vaginal 
fluid from 6 Black and 6 White females and compared their antiviral effects against the 7 clinical 
strains of HIV previously shown to be inhibited by the mixed pools of vaginal fluid. Figure 2 
shows a notable difference in the activity of vaginal fluid from Black and White females in viral 
inhibition. Although both pools inhibit infection at >80% for the highest vaginal fluid 
concentration, vaginal fluid pooled from White females consistently shows greater inhibition of 
all clinical strains compared to vaginal fluid pooled from Black women. The difference in 
antiviral activity of 5% vaginal fluid was significant for 3 out of the 7 clinical HIV isolates 
tested. Interestingly, 2 out of these 3 clinical isolates were A clade viruses, while the remaining 
clinical isolate was a B clade virus. 
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Figure 2. Vaginal Fluid From White Females Shows Greater HIV Inhibition than Vaginal Fluid from Black Females. 
Vaginal fluid pooled from either White or Black donors was assayed for antiviral activity. Infection was quantified by measuring 
luciferase expression in each condition. Values were normalized to a media-only control and expressed as percent inhibition (n=3). 
The clade of each clinical strain is given in parentheses. Error bars represent the SEM. Significant differences in inhibition between 
Black and White vaginal fluid pools in a two-tailed t-test are shown by  *=p<0.05; **=p<0.01  
 
13 
 
 Tests for viability were performed in parallel to ensure that vaginal fluid did not exhibit 
cytotoxic effects on TZM-bl cells. Cell viability was established by trypan blue exclusion assay 
where the number of live cells were counted for each condition that received vaginal fluid and 
normalized to a media-only control. Figure 3 reveals that vaginal fluid did not induce any 
cytotoxic effects on the cells.  
 
 
Figure 3. Acid-extracted Vaginal Fluid Is Non-cytotoxic to TZM-bl Cells.  
Cells were treated in parallel to antiviral experiments, without addition of virus. Cell viability 
was determined by trypan blue exclusion assay. The number of live cells in each condition was 
normalized to a media-only control and values were expressed as percent viability (n=3). Error 
bars represent the SEM. Significant differences by a two-tailed t-test between vaginal fluid and 
PBS (vehicle) treatments are shown by *=p<0.05 
 
 Interestingly, vaginal fluid at a concentration of 1.25% appeared to stimulate cell growth 
compared to the PBS treatment. Factors responsible for this proliferative effect have yet to be 
identified. Together, these results indicate that vaginal fluid confers protection against HIV 
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infection to the female host; however, the antiviral activity of vaginal fluid from Black women is 
less effective at inhibiting HIV infection compared to vaginal fluid from White women. 
 These results emphasize that vaginal fluid, rich in antimicrobial peptides, represents an 
essential immune component that protects the mucosal surfaces of the vagina from HIV 
infection. Another equally important element that helps maintain the integrity of the FRT is the 
commensal bacterial flora that colonize and protect the vagina. 
RC-101 Remains Intact in the Presence of BV-associated Bacteria  
 BV is a prevalent condition in females that can disrupt the healthy vaginal microbiota and 
increase host susceptibility to HIV acquisition. Previous studies have shown that women with 
BV have vaginal fluid lacking in important antimicrobial peptides compared to healthy women 
(18). This establishes a possible mechanism by which BV compromises innate defenses and 
increases host susceptibility to HIV infection. Thus, supplementing vaginal fluid with 
antimicrobial peptides may reestablish full innate immune competence in the FRT. To assess the 
potential of RC-101 as a therapy for women with BV, we first determined the ability of the 
peptide to remain intact in the presence of common BV-associated bacteria. BV-associated 
bacteria, represented by M. curtisii, A. vaginae, P. bivia, and G. vaginalis were incubated for 24 
hrs with RC-101; samples were subsequently acid-extracted and western blotted to detect the 
presence of RC-101. Figure 4 shows the peptide  was recovered from all the culture conditions 
incubated with RC-101 and that the peptide migrated along side the RC-101 standard. These 
results suggest that RC-101 remains intact in the presence of pathogenic bacteria.  
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Figure 4. RC-101 Remains Intact in the Presence of Pathogenic Bacteria.  
RC-101 was incubated in cultures of BV-associated bacteria. Cultures were acid-extracted and 
analyzed by western blot alongside an equivalent RC-101 standard. The blot shown is one 
representative of three independent experiments. 
RC-101 Inhibits the Growth of Anaerobic Pathogenic Bacteria 
 After establishing that RC-101 is not degraded by BV-associated bacteria, we next tested 
the effectiveness of the peptide in inhibiting the growth of pathogenic bacteria. M. curtisii, A. 
vaginae, and P. bivia were incubated with different RC-101 concentrations for up to 24 hrs. 
These bacteria were also incubated with 0.5 μg/ml of clindamycin, the standard antibiotic used to 
treat BV. Culture density was determined for all conditions and the results were reported as 
percent inhibition compared to untreated culture controls. Figure 5 shows that RC-101 
effectively restricts the growth of all three bacteria at 24 hrs.  
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Figure 5. RC-101 Inhibits the Growth of Pathogenic Bacteria.  
BV-associated bacteria M. curtisii, A. vaginae, and P. bivia were incubated with RC-101 or 
clindamycin for up to 24 hrs and plated to assess culture growth. Results are shown as percent 
inhibition compared to untreated cultures. Percent inhibition values lower than zero were plotted 
as zero percent inhibition. 
 
 RC-101 inhibits the growth of all pathogenic bacteria tested. At 24 hrs, 10 μg/ml RC-101 
achieved >40% inhibition of all three bacteria. Additionally, RC-101 at 5 μg/ml and 10 μg/ml 
exhibited significantly greater inhibition of M. curtisii than clindamycin. Importantly, other data 
from our group (C.R.E., not shown) revealed that RC-101 at the same concentrations tested 
above does not inhibit the growth of 6 Lactobacillus spp, commensal bacteria found in the 
vagina. Collectively, these data suggest that RC-101 can act as a selective bactericidal agent, 
effectively inhibiting the growth of common pathogenic bacteria while leaving the protective 
microflora of the female vagina intact.  
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CHAPTER FOUR: DISCUSSION 
 The innate immunity of the FRT plays an essential role in determining host susceptibility 
to HIV acquisition. Vaginal fluid represents one protective immune component that maintains 
the integrity of the FRT and strengthens host defenses against foreign invaders. Our studies 
suggest that vaginal fluid from both Black and White females is active against infection by 
diverse HIV clinical strains. Yet, we showed that vaginal fluid from both races does not possess 
equal antiviral activity against HIV infection. Vaginal fluid from Black females consistently 
exhibited lower inhibition of HIV compared to vaginal fluid from White females. This difference 
in antiviral activity of vaginal fluid has profound implications for Black women, who may be 
more susceptible to HIV acquisition compared to their White counterparts. In support of this, 
African Americans are the group most affected by new HIV infections in the United States. In 
fact, the rate of HIV acquisition for African American women is significantly greater compared 
to White women (21). Although socioeconomic factors cannot be discounted as contributing 
factors for the observed differences in HIV infections between women of different races, our 
findings suggest the possibility that variations in innate immune components of the genital 
mucosa among White and Black women may contribute to this discrepancy in HIV transmission. 
Moreover, such susceptibility differences may contribute to the strikingly high rate of HIV 
occurrence in Black women across the globe. 
 In addition to investigating vaginal fluid as an innate immune component of the FRT, we 
also explored the ability of the microbicide candidate RC-101 in maintaining the integrity of the 
FRT. Another aspect of female innate immunity that plays an essential role in HIV protection is 
the commensal resident microbiota of the vagina. Previous studies have shown that when the 
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healthy bacterial flora is disrupted, vaginal fluid lacks key antimicrobial peptides, which may 
lead to a higher risk of HIV infection (24). As a result, developing an effective treatment that 
combats BV and maintains the integrity of the FRT is an important step in decreasing female 
susceptibility to HIV acquisition. In our study, we assessed the ability of the anti-HIV 
microbicide RC-101 to inhibit the growth of pathogenic bacteria commonly associated with BV. 
Interestingly, at 24 hrs the highest concentrations of the peptide significantly inhibited the 
growth of M. curtisii compared to clindamycin, which is the preferred treatment for BV. Our 
studies further suggest that RC-101 remains intact in the presence of M. curtisii, A. vaginae, P. 
bivia, or G. vaginalis, all pathogenic bacteria characteristically present in BV. These findings 
make RC-101 a potent prophylactic agent which may possess a dual mechanism of protection 
against HIV infection by both directly preventing viral entry, and by restricting the growth of 
pathogenic bacteria that disrupt protective commensal vaginal flora. Collectively, these findings 
elucidate novel mechanisms of HIV protection that warrant further investigation. 
 The observed difference in anti-HIV activity of vaginal fluid from Black and White 
women sets the stage for future studies that will characterize protein differences in vaginal fluid 
from these two races. Such disparities in protein content may contribute to a higher risk of HIV 
infection in Black females. In addition, future studies on RC-101 will determine the ability of 
this microbicide to inhibit the growth of BV-associated bacteria in the presence of vaginal fluid 
and explore possible synergistic effects with endogenous host defense peptides. Overall, these 
studies will contribute to a greater understanding of host-HIV interactions that elucidate 
promising targets for the prevention of HIV transmission. 
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APPENDIX: RACIAL AND ETHNIC COMPOSITION OF VAGINAL 
FLUID POOLS 
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 Race Ethnicity 
Pool White Black Unknown Hispanic Not 
Hispanic 
Unknown 
Mix 1 6 (50%) 6 (50%) 0 (0%) 1 (8%) 5 (42%) 6 (50%) 
Mix 2 6 (50%) 6 (50%) 0 (0%) 2 (16%) 5 (42%) 5 (42%) 
Mix 3 5 (42%) 6 (50%) 1 (8%) 1 (8%) 5 (42%) 6 (50%) 
B1 0 (0%) 6 (100%) 0 (0%) 0 (0%) 4 (67%) 2 (33%) 
W1 6 (100%) 0 (0%) 0 (0%) 2 (33%) 1 (17%) 3 (50%) 
B2 0 (0%) 6 (100%) 0 (0%) 0 (0%) 4 (67%) 2 (33%) 
W2 6 (100%) 0 (0%) 0 (0%) 0 (0%) 4 (67%) 2 (33%) 
B3 0 (0%) 6 (100%) 0 (0%) 0 (0%) 5 (83%) 1 (17%) 
W3 6 (100%) 0 (0%) 0 (0%) 1 (17%) 2 (33%) 3 (50%) 
 
Table 2. Racial and Ethnic Composition of Vaginal Fluid Pools. 
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